GELNIQUE
OXYBUTYNIN CHLORIDE
Approval overview GELNIQUE is listed in Drugs@FDA under application 022204 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient OXYBUTYNIN CHLORIDE Form and strength GEL;TRANSDERMAL - 10% (100MG/PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ABBVIE Submission history Latest submission status date: 2017-10-25 00:00:00.
Structured Monograph
Clinical summary
Approval overview GELNIQUE is listed in Drugs@FDA under application 022204 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient OXYBUTYNIN CHLORIDE Form and strength GEL;TRANSDERMAL - 10% (100MG/PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ABBVIE Submission history Latest submission status date: 2017-10-25 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.